These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 9444439)

  • 1. Doxazosin for benign prostatic hyperplasia in primary care.
    Guthrie R
    Clin Ther; 1997; 19(6):1269-77; discussion 1253-4. PubMed ID: 9444439
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A multicenter, community-based study of doxazosin in the treatment of concomitant hypertension and symptomatic benign prostatic hyperplasia: the Hypertension and BPH Intervention Trial (HABIT).
    Guthrie RM; Siegel RL
    Clin Ther; 1999 Oct; 21(10):1732-48. PubMed ID: 10566569
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Doxazosin-alpha-1-adrenergic antagonists drug in the long-term (3 years). Management of benign prostatic hyperplasia.
    Dutkiewicz S
    Mater Med Pol; 1996; 28(3):93-102. PubMed ID: 9167419
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The treatment of benign prostatic hyperplasia with alpha blockers in men over the age of 80 years.
    Kaplan SA; Te AE; Ikeguchi E; Santarosa RP
    Br J Urol; 1997 Dec; 80(6):875-9. PubMed ID: 9439400
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term treatment with doxazosin in men with benign prostatic hyperplasia: 10-year follow-up.
    Dutkiewicz S
    Int Urol Nephrol; 2004; 36(2):169-73. PubMed ID: 15368687
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term (4 year) efficacy and tolerability of doxazosin for the treatment of concurrent benign prostatic hyperplasia and hypertension.
    Fawzy A; Hendry A; Cook E; Gonzalez F
    Int J Urol; 1999 Jul; 6(7):346-54. PubMed ID: 10445304
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of doxazosin on the symptoms of benign prostatic hyperplasia: results from three double-blind placebo-controlled studies.
    Mobley DF; Kaplan S; Ice K; Gaffney M; Dias N
    Int J Clin Pract; 1997; 51(5):282-8. PubMed ID: 9489085
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Profile of doxazosin in patients with benign prostatic hyperplasia.
    Janknegt RA
    Scand J Urol Nephrol Suppl; 1995; 168():21-7. PubMed ID: 7541548
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Doxazosin--an alpha-1 receptor blocking agent in the long-term management of benign prostatic hyperplasia (Part One).
    Dutkiewicz S; Witeska A
    Int Urol Nephrol; 1995; 27(3):311-8. PubMed ID: 7591596
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Doxazosin: a new approach to hypertension and benign prostatic hyperplasia.
    Pool JL
    Br J Clin Pract; 1996; 50(3):154-63. PubMed ID: 8733335
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Double-blind trial of the efficacy and tolerability of doxazosin in the gastrointestinal therapeutic system, doxazosin standard, and placebo in patients with benign prostatic hyperplasia.
    Andersen M; Dahlstrand C; Høye K
    Eur Urol; 2000 Oct; 38(4):400-9. PubMed ID: 11025377
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The early effects of doxazosin on benign prostatic hyperplasia.
    Akan H; Başar M; Dalva I; Başar H
    Arch Ital Urol Androl; 1998 Feb; 70(1):41-4. PubMed ID: 9549168
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Experience in the use of doxazosin in patients with benign hyperplasia of the prostate].
    Lopatkin NA; Loran OB; Pushkar' DIu; Perepanova TS; Tevlin KP
    Urol Nefrol (Mosk); 1998; (3):3-5. PubMed ID: 9644978
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Doxazosin in the gastrointestinal therapeutic system (GITS) and doxazosin standard in patients with benign prostatic hyperplasia. Double-blind trial of efficacy and tolerability].
    Gratzke P; Kirby RS
    Fortschr Med Orig; 2000 Jul; 118 Suppl 2():83-92. PubMed ID: 15700491
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A comparative study of: long-term alpha-1-blocker, Doxazosin therapy versus surgery in the treatment of benign prostatic hyperplasia.
    Dutkiewicz S
    Mater Med Pol; 1995; 27(4):151-2. PubMed ID: 9000839
    [TBL] [Abstract][Full Text] [Related]  

  • 16. After ALLHAT: doxazosin for the treatment of benign prostatic hyperplasia.
    Doggrell SA
    Expert Opin Pharmacother; 2004 Sep; 5(9):1957-64. PubMed ID: 15330733
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Doxazosin in physiologically and pharmacologically normotensive men with benign prostatic hyperplasia.
    Kaplan SA; Meade-D'Alisera P; Quiñones S; Soldo KA
    Urology; 1995 Oct; 46(4):512-7. PubMed ID: 7571220
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Induction of prostate apoptosis by doxazosin in benign prostatic hyperplasia.
    Kyprianou N; Litvak JP; Borkowski A; Alexander R; Jacobs SC
    J Urol; 1998 Jun; 159(6):1810-5. PubMed ID: 9598465
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of the alpha-1 blocker doxazosin in the treatment of benign prostatic hyperplasia. Analysis of 5 studies. Doxazosin Study Groups.
    Janknegt RA; Chapple CR
    Eur Urol; 1993; 24(3):319-26. PubMed ID: 7505224
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Doxazosin--an alpha-1 receptor blocking agent in the long-term management of benign prostatic hyperplasia (BPH) (Part Two).
    Dutkiewicz S; Witeska A; Stepień K
    Int Urol Nephrol; 1995; 27(4):413-7. PubMed ID: 8586513
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.